Certain HIV Meds May Trigger Weight Gain webmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webmd.com Daily Mail and Mail on Sunday newspapers.
March 16, 2021
Between 1 and 2 years, the device-oriented advantage offered by an ultrathin-strut, biodegradable-polymer DES continues to accrue in patients treated for STEMI, the latest data from the BIOSTEMI trial show.
At 2 years, the rate of target lesion failure was 5.1% with the sirolimus-eluting Orsiro stent (Biotronik) and 8.1% with the thin-strut, durable-polymer, everolimus-eluting Xience Xpedition/Alpine (Abbott) stent, Thomas Pilgrim, MD (Bern University Hospital, Switzerland), reported this weekend during the virtual CRT 2021 meeting. At 1 year, the rates were 4% and 6% respectively.
“When we look at a landmark analysis with a time point at 1 year, we see actually that the difference still accrues over time,” senior investigator Juan F. Iglesias, MD (Geneva University Hospitals, Switzerland), told TCTMD. “The curves are still diverging,” which he said supports the idea that small differences in stent design can impact prognosis.
A new method for controlling leukemic stem cells
Leukemia is caused by leukemic stem cells which are resistant to most known therapies. Relapses are also due to this resistance. Leukemic stem cells arise from normal blood-forming (hematopoietic) stem cells.
Because they are closely related, leukemic and hematopoietic stem cells share many of the same signaling pathways. If the proliferation of leukemic stem cells is to be stopped, it is crucial to find signaling pathways that are active only in the leukemic stem cell, but not the normal one.
With this goal in mind, Prof. Adrian Ochsenbein and his team are conducting research at the Department of Medical Oncology at Inselspital, Bern University Hospital. The latest discovery, the so-called LIGHT/LTbR pathway, is presented in Sabine Höpner s article published today in
Anti-emetic drug offers a promising approach to treat chronic myeloid leukemia
Chronic myeloid leukemia (CML) results from a degeneration of the hematopoietic stem cells (leukemia stem cells), thereby leading to the uncontrolled formation of specific white blood cells, the so-called granulocytes.
Research work at the Department of Medical Oncology at the Inselspital, Bern University Hospital and the University of Bern focused therefore on identifying the signaling pathways and control mechanisms of the leukemia stem cell. A promising approach is provided by working with MPR, an anti-emetic medication commonly used to treat nausea and vomiting.
Specific blocking of leukemia stem cell proliferation with metoclopramide
E-Mail
Chronic myeloid leukemia (CML) results from a degeneration of the hematopoietic stem cells (leukemia stem cells), thereby leading to the uncontrolled formation of specific white blood cells, the so-called granulocytes. Research work at the Department of Medical Oncology at the Inselspital, Bern University Hospital and the University of Bern focused therefore on identifying the signaling pathways and control mechanisms of the leukemia stem cell. A promising approach is provided by working with MPR, an anti-emetic medication commonly used to treat nausea and vomiting.
Specific blocking of leukemia stem cell proliferation with metoclopramide
The exact role of the surface molecule CD93 (cluster of differentiation 93) in controlling the proliferation of leukemia stem cells was analyzed and documented, initially in animal experiments and subsequently in experiments with leukemia stem cells from patients. This revealed a distinct regulatory function of CD93 in leukemia stem cel